News
As Novo Nordisk works through a period of transition in the U.S. GLP-1 drug market, sales from the company's star obesity ...
Novo Nordisk cut 2025 sales forecast citing competition from compounded versions of its Wegovy weight-loss drug. Invezz takes ...
Wegovy (semaglutide) could offer a new option to treat severe liver disease based on new clinical trial evidence. The GLP-1 ...
The FDA in February formally declared the end of the semaglutide shortage, which Novo Nordisk expects will help improve the ...
My doctor said patients have told him they were able to stop drinking and even quit cocaine use while taking Wegovy.
Novo Nordisk’s oral Wegovy pill for chronic weight loss is under FDA review. If approved, it would be the first oral GLP-1 ...
Prior to starting the trial, the participants also had moderate to high levels of scar tissue in the liver, known as stage 2 ...
A large trial showed that the weight-loss drug could reduce liver inflammation and scarring caused by the common condition.
MedPage Today on MSN1d
Wegovy Pill Under Review; FDA Lifts Obesity Trial Clinical Hold; SGLT2s and SurgeryThe FDA will decide whether to approve a once-daily, 25 mg oral formulation of semaglutide (Wegovy) by the end of 2025. If ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback